FibroBiologics Announces Pricing of $3 Million Public Offering
FibroBiologics, a clinical-stage biotechnology company specializing in fibroblast-based therapeutics, announced the pricing of a best efforts public offering to raise approximately $3 million through the sale of shares and warrants. The offering is subject to stockholder approval and expected to close around April 2, 2026. Net proceeds will be used…